BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and commercial...
BioCentury | Aug 5, 2013
Strategy

Antibiotic aggregator

...submit an NDA for both indications six months later. Also in Phase III testing are surotomycin...
...like patients who have relapsed multiple times. Dificid should be a good complement for Cubist's surotomycin...
BioCentury | Mar 11, 2013
Clinical News

Surotomycin regulatory update

...FDA granted Fast Track designation for surotomycin to treat Clostridium difficile-associated diarrhea (CDAD). Surotomycin is an...
...Dec. 17, 2012). Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Product: Surotomycin ( CB-315 ) (formerly CB-183,315...
BioCentury | Jan 7, 2013
Finance

Buyside View XXI: Sunny side up

...in revenues for the first nine months of 2012. The other Phase III program is CB-315...
BioCentury | Dec 17, 2012
Clinical News

CB-315 regulatory update

...for CB-315 to treat Clostridium difficile-associated diarrhea (CDAD) and CXA-201 to treat complicated intra-abdominal infection. CB-315...
...signed into law earlier this year. Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Product: CB-315 (formerly CB-183,315...
BioCentury | Jul 16, 2012
Clinical News

CB-315: Phase III started

...of a pair of identical, double-blind, international Phase III trials to compare 250 mg twice-daily CB-315...
...10 days in 608 patients each. Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Product: CB-315 (formerly CB-183,315...
BioCentury | Jun 18, 2012
Company News

Cubist infectious news

...two products in Phase II testing: CB-5945 , an OPRM1 antagonist for opioid-induced constipation; and CB-183,315...
BioCentury | Jun 12, 2012
Company News

Cubist outlines five-year strategy

...UTI). The company has two products in Phase II testing: CB-5945 for opioid-induced constipation; and CB-183,315...
BioCentury | Jun 20, 2011
Finance

Highlights of weekly biotech stock moves

...complicated urinary tract infections (cUTIs) by year end (see B17) . Separately, Cubist said its CB-183,315...
...company plans to announce by year end whether it will start Phase III testing of CB-183,315...
BioCentury | Jun 20, 2011
Clinical News

CB-183: Phase II data

...Canadian Phase II trial in 209 patients showed that twice-daily 125 and 250 mg oral CB-183,315...
...lower recurrence rate vs. Vancocin (17% vs. 36%, p=0.035), but low-dose CB-183,315 did not (28%). CB-183,315...
...Cubist plans to announce a formal decision on whether to start Phase III testing with CB-183,315...
Items per page:
1 - 10 of 15